Oracle / OCI reported capital expenditure of $55.66B for fiscal 2026, +162.4% versus $21.21B in fiscal 2025.
Capex equals 83% of fiscal-year revenue ($67.36B).
The highest single reported period was $28.50B (period ending 2026-08-31).
The latest reported period, 2026Q1, shows $28.50B; the dataset covers 66 reported periods (2010–2026), all from SEC XBRL filings.
Every capital-expenditure figure Oracle / OCI has reported to the SEC, unedited. Capex is the XBRL concept PaymentsToAcquirePropertyPlantAndEquipment; a capex/revenue ratio above 100% means the company is investing more than it earns to secure capacity. Each row links to the filing it came from.
| Fiscal year | Capex | YoY |
|---|---|---|
| FY2026 | $55.66B | +162% |
| FY2025 | $21.21B | +209% |
| FY2024 | $6.87B | -21% |
| FY2023 | $8.70B | +93% |
| FY2022 | $4.51B | +111% |
| FY2021 | $2.13B | +37% |
| FY2020 | $1.56B | -6% |
| FY2019 | $1.66B | -4% |
| FY2018 | $1.74B | -14% |
| FY2017 | $2.02B | +70% |
| FY2016 | $1.19B | -15% |
| FY2015 | $1.39B | +140% |
| FY2014 | $580M | -11% |
| FY2013 | $650M | 0% |
| FY2012 | $648M | +44% |
| FY2011 | $450M | +96% |
| FY2010 | $230M | — |
| Period end | Period | Capex |
|---|---|---|
| 2026-08-31 | FY2026 Q1 | $28.50B |
| 2026-05-31 | FY2026 FY | $55.66B |
| 2026-02-28 | FY2026 9 mo. cumulative | $39.17B |
| 2025-11-30 | FY2025 6 mo. cumulative | $20.54B |
| 2025-08-31 | FY2025 Q1 | $8.50B |
| 2025-05-31 | FY2025 FY | $21.21B |
| 2025-02-28 | FY2025 9 mo. cumulative | $12.13B |
| 2024-11-30 | FY2024 6 mo. cumulative | $6.27B |
| 2024-08-31 | FY2024 Q1 | $2.30B |
| 2024-05-31 | FY2024 FY | $6.87B |
| 2024-02-29 | FY2024 9 mo. cumulative | $4.07B |
| 2023-11-30 | FY2023 6 mo. cumulative | $2.39B |
| 2023-08-31 | FY2023 Q1 | $1.31B |
| 2023-05-31 | FY2023 FY | $8.70B |
| 2023-02-28 | FY2023 9 mo. cumulative | $6.78B |
| 2022-11-30 | FY2022 6 mo. cumulative | $4.15B |
| 2022-08-31 | FY2022 Q1 | $1.72B |
| 2022-05-31 | FY2022 FY | $4.51B |
| 2022-02-28 | FY2022 9 mo. cumulative | $3.09B |
| 2021-11-30 | FY2021 6 mo. cumulative | $1.99B |
| 2021-08-31 | FY2021 Q1 | $1.06B |
| 2021-05-31 | FY2021 FY | $2.13B |
| 2021-02-28 | FY2021 9 mo. cumulative | $1.42B |
| 2020-11-30 | FY2020 6 mo. cumulative | $1.00B |
| 2020-08-31 | FY2020 Q1 | $436M |
| 2020-05-31 | FY2020 FY | $1.56B |
| 2020-02-29 | FY2020 9 mo. cumulative | $1.13B |
| 2019-11-30 | FY2019 6 mo. cumulative | $735M |
| 2019-08-31 | FY2019 Q1 | $386M |
| 2019-05-31 | FY2019 FY | $1.66B |
| 2019-02-28 | FY2019 9 mo. cumulative | $1.25B |
| 2018-11-30 | FY2018 6 mo. cumulative | $804M |
| 2018-08-31 | FY2018 Q1 | $383M |
| 2018-05-31 | FY2018 FY | $1.74B |
| 2018-02-28 | FY2018 9 mo. cumulative | $1.36B |
| 2017-11-30 | FY2017 6 mo. cumulative | $1.07B |
| 2017-08-31 | FY2017 Q1 | $473M |
| 2017-05-31 | FY2017 FY | $2.02B |
| 2017-02-28 | FY2017 9 mo. cumulative | $1.50B |
| 2016-11-30 | FY2016 6 mo. cumulative | $1.06B |
| 2016-08-31 | FY2016 Q1 | $299M |
| 2016-05-31 | FY2016 FY | $1.19B |
| 2016-02-29 | FY2016 9 mo. cumulative | $1.01B |
| 2015-11-30 | FY2015 6 mo. cumulative | $641M |
| 2015-08-31 | FY2015 Q1 | $446M |
| 2015-05-31 | FY2015 FY | $1.39B |
| 2015-02-28 | FY2015 9 mo. cumulative | $794M |
| 2014-11-30 | FY2014 6 mo. cumulative | $426M |
| 2014-08-31 | FY2014 Q1 | $201M |
| 2014-05-31 | FY2014 FY | $580M |
| 2014-02-28 | FY2014 9 mo. cumulative | $426M |
| 2013-11-30 | FY2013 6 mo. cumulative | $279M |
| 2013-08-31 | FY2013 Q1 | $153M |
| 2013-05-31 | FY2013 FY | $650M |
| 2013-02-28 | FY2013 9 mo. cumulative | $467M |
| 2012-11-30 | FY2012 6 mo. cumulative | $351M |
| 2012-08-31 | FY2012 Q1 | $139M |
| 2012-05-31 | FY2012 FY | $648M |
| 2012-02-29 | FY2012 9 mo. cumulative | $431M |
| 2011-11-30 | FY2011 6 mo. cumulative | $289M |
| 2011-08-31 | FY2011 Q1 | $160M |
| 2011-05-31 | FY2011 FY | $450M |
| 2011-02-28 | FY2011 9 mo. cumulative | $372M |
| 2010-11-30 | FY2010 6 mo. cumulative | $239M |
| 2010-08-31 | FY2010 Q1 | $118M |
| 2010-05-31 | FY2010 FY | $230M |
Source: SEC XBRL company-concept API, concept PaymentsToAcquirePropertyPlantAndEquipment, CIK 1341439. See Methodology.